Who mentions $CLPT most on Surfaced?

@investmentguru_ (InvestmentGuru) mentions $CLPT most — 22 mentions in the past 12 months.

When was $CLPT first mentioned on Surfaced?

The earliest tracked mention of $CLPT in the Surfaced archive was on Aug 20, 2025.

How many voices track $CLPT?

8 FinTwit voices have mentioned $CLPT 43 times in the past 12 months.

What kind of voices mention $CLPT most?

$CLPT is mentioned most by Long Research voices on Surfaced.

Last 12mo stats

mentions

voices

$CLPT

Clearpoint Neuro

$CLPT

Clearpoint Neuro

Past 12mo:43mentions8voices

All voices5 calls since Dec 2025show all

Loading price chart…

About this stock

$CLPT has been discussed across 8 distinct FinTwit voices over the past 12 months, with 43 total mentions spanning from August 20, 2025 to July 11, 2026. The most active voice discussing the company is @investmentguru_, who has posted about $CLPT 22 times, followed by @stocksavvyshay with 11 mentions. The dominant discussion category centers on long research, with @kaizen_investor, @microcapclub, and @adamfeuerstein each contributing additional commentary. The ticker first appeared in the archive on August 20, 2025.

AI-generated from tracked posts · updated Jul 12, 2026

Frequently asked

Related stocks

$QUREuniQure

$NTLAIntellia Therapeutics

$PRMEPrime Medicine

$VKTXViking Therapeutics

Recent calls

5 calls

@stocksavvyshayJun 17, 2026 · 2:27 PM

@RetailKingsETF This is super bullish for $CLPT because they own the delivery bottleneck for AMT-130.

Open on X

@kaizen_investorMar 17, 2026 · 8:26 PM

$CLPT just dropped their Q4 2025 results. The stock is down 5%. They hit record sales of $37 million, marking their 11th straight year of growth. Their core business of helping surgeons navigate the brain is thriving, and their recent IRRAS acquisition gives them even more tools. On the other side, their financial losses widened to $25.5 million because they are spending heavily to integrate the new business, develop technology, and hire more staff.

Open on X

@stocksavvyshayMar 6, 2026 · 11:36 PM

$CLPT up 30% after reports FDA official Vinay Prasad will leave the agency at the end of April Prasad had become a major flashpoint over oversight of rare disease drugs making his exit a potential regulatory overhang removal for the space. https://t.co/IVjO3LiD3g

Open on X

@investmentguru_Jan 7, 2026 · 11:55 AM

$CLPT ClearPoint Neuro represents a compelling long-term growth story at the intersection of medical devices and advanced therapeutics. The company provides precision hardware and consumables used for accurate delivery of drugs, cell therapies, and gene therapies to the brain and spine—technologies that are becoming foundational in modern neuroscience treatments. What makes $CLPT particularly attractive is its embedded growth model: its systems are adopted early in clinical trials and, once therapies receive FDA approval, ClearPoint’s platforms often become a permanent part of the treatment protocol. This creates high switching costs, recurring consumable revenue, and strong long-term visibility. Despite these structural advantages and optionality tied to the expanding cell and gene therapy pipeline, the stock has fallen out of favor amid the broader healthcare sector downturn—potentially setting up an opportunity for patient, long-term investors as adoption and approvals scale over time. Not a financial advice

Open on X

@investmentguru_Dec 17, 2025 · 11:24 AM

$CLPT looks compelling long term - Pure-play in precision neuroscience ClearPoint is focused on MRI-guided neurosurgical navigation, enabling minimally invasive, highly accurate brain procedures. This is not hype tech — it’s real clinical adoption. - Platform play, not one product ClearPoint’s system supports gene therapy, drug delivery, DBS, and emerging neuro treatments. As neuroscience innovation accelerates, CLPT benefits across multiple therapies. - Partnered with the future of medicine Used by leading academic hospitals and biotech partners working on Alzheimer’s, Parkinson’s, brain tumors, and rare neuro diseases. If neuro pipelines succeed, CLPT becomes the picks-and-shovels winner. - High switching costs + sticky adoption Once hospitals adopt ClearPoint’s workflow, it’s embedded into surgical planning — creating durable, repeat usage over time. - Early-stage growth, massive runway Neuro is one of the largest unmet medical markets, and precision delivery will be critical for next-gen therapies. $CLPT is a quiet neurotech compounder — enabling breakthroughs rather than betting on a single drug. As neuroscience advances, ClearPoint sits right at the center. High impact. High conviction. Long-term vision.

Open on X